Enzastaurin, a protein kinase Cβ-selective inhibitor, and its potential application as an anticancer agent in lung cancer

Clinical Cancer Research

Volumn 13, Issue 15, 2007, Pages

  Herbst, Roy S ^a   Oh, Yun ^a   Wagle, Asavari ^b   Lahn, Michael ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CARBOPLATIN; CISPLATIN; ENZASTAURIN; GEMCITABINE; ISIS 3521; PACLITAXEL; PEMETREXED; PROTEIN KINASE C INHIBITOR;

AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; CARDIOTOXICITY; CHROMATURIA; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FATIGUE; HUMAN; LIVER TOXICITY; LOADING DRUG DOSE; LUNG CANCER; MIGRAINE; MOTOR NEUROPATHY; NEUTROPENIA; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STEADY STATE; THROMBOCYTOPENIA; URINE COLOR;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; HUMANS; INDOLES; LUNG NEOPLASMS; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS;

EID: 34547670598     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0538     Document Type: Article

References (62)

1. Parker PJ, Murray-Rust J. PKC at a glance. J Cell Sci 2004;117:131-2.
2. Livneh E, Fishman DD. Linking protein kinase C to cell-cycle control. Eur J Biochem 1997;248:1-9.
3. Murray NR, Davidson LA, Chapkin RS, et al. Overexpression of protein kinase C hII induces colonic hyperproliferation and increased sensitivity to colon carcinogenesis. J Cell Biol 1999;145:699-711.
4. Goekjian PG, Jirousek MR. Protein kinase C inhibitors as novel anticancer drugs. Expert Opin Investig Drugs 2001;10:2117-40.
5. Castagna M, Takai Y, Kaibuchi K, et al. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J Biol Chem 1982;257:7847-51.
6. Cho KK, Mikkelsen T, Lee YJ, et al. The role of protein kinase C-α in U-87 glioma invasion. Int J Dev Neurosci 1999;17:447-61.
7. Chang PL, Chambers AF. Transforming JB6 cells exhibit integrin-mediated adhesion to osteopontin. J Cell Biochem 2000;78:8-23.
8. Park MJ, Park IC, Hur JH, et al. Protein kinase C activation by phorbol ester increases in vitro invasion through regulation of matrix metalloproteinases/tissue inhibitors of metalloproteinases system in D54 human glioblastoma cells. Neurosci Lett 2000;290:201-4.
9. Murray NR, Jamieson L, Yu W, et al. Protein kinase Ci is required for Ras transformation and colon carcinogenesis in vivo. J Cell Biol 2004;164:797-802.
10. Gokmen-Polar Y, Murray NR, Velasco MA, et al. Elevated protein kinase CβII is an early promotive event in colon carcinogenesis. Cancer Res 2001;61:1375-81.
11. Engers R, Mrzyk S, Springer E, et al. Protein kinase C in human renal cell carcinomas: role in invasion and differential isoenzyme expression. Br J Cancer 2000;82:1063-9.
12. Tsai JH, Hsieh YS, Kuo SJ, et al. Alteration in the expression of protein kinase C isoforms in human hepatocellular carcinoma. Cancer Lett 2000;161:171-5.
13. Clark AS, West KA, Blumberg PM, et al. Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCδ promotes cellular survival and chemotherapeutic resistance. Cancer Res 2003;63:780-6.
14. Koren R, Ben Meir D, Langzam L, et al. Expression of protein kinase C isoenzymes in benign hyperplasia and carcinoma of the prostate. Oncol Rep 2004;11:321-6.
15. Balendran A, Hare GR, Kieloch A, et al. Further evidence that 3-phosphoinositide-dependent protein kinase-1 (PDK1) is required for the stability and phosphorylation of protein kinase C (PKC) isoforms. FEBS Lett 2000;484:217-23.
16. Partovian C, Simons M. Regulation of protein kinase B/Akt activity and Ser473 phosphorylation by protein kinase Ca in endothelial cells. Cell Signal 2004;16:951-7.
17. Kawakami Y, Nishimoto H, Kitaura J, et al. Protein kinase C BII regulates Akt phosphorylation on Ser-473 in a cell type- and stimulus-specific fashion. J Biol Chem 2004;279:47720-5. Epub 2004 Sep 09.
18. Fang X, Yu S, Tanyi JL, et al. Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway. Mol Cell Biol 2002;22:2099-110.
19. Xia P, Aiello LP, Ishii H, et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 1996;98:2018-26.
20. Yoshiji H, Kuriyama S, Ways DK, et al. Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res 1999;59:4413-8.
21. Zhang J, Anastasiadis PZ, Liu Y, et al. Protein kinase C (PKC) BII induces cell invasion through a Ras/Mek-, PKCι/Rac1-dependent signaling pathway. J Biol Chem 2004;279:22118-23. Epub 2004 Mar 22.
22. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68-74.
23. Li S, Phong M, Lahn M, et al. Retrospective analysis of protein kinase C-β (PKC-β) expression in lymphoid malignancies and its association with survival in diffuse large B-cell lymphomas. Biology Direct 2007;2:8.
24. Faul MM, Gillig JR, Jirousek MR, et al. Acyclic N-(azacycloalkyl) bisindolylmaleimides: isozyme selective inhibitors of PKCβ. Bioorg Med Chem Lett 2003;13:1857-9.
25. Graff JR, McNulty AM, Hanna KR, et al. The protein kinase Cβ-selective inhibitor, enzastaurin (LY317615. HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005;65:7462-9.
26. Hanauske A, Oberscchmidt O, Hanauske-Abel H, et al. Antitumor activity of enzastaurin (LY317615.HCl) against human cancer cell lines and freshly explanted tumors investigated in vitro soft-agar cloning experiments. Invest New Drugs 2007;25:205-10. Epub 2007 March 9.
27. Nakajima E, Helfrich B, Chan D, et al. Enzastaurin a protein kinase Cβ-selective inhibitor, inhibits the growth of SCLC and NSCLC cell lines [abstract 13138]. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006.
28. Keyes KA, Mann L, Sherman M, et al. LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother Pharmacol 2004;53:133-40.
29. Teicher BA, Alvarez E, Menon K, et al. Antiangiogenic effects of a protein kinase Cβ-selective small molecule. Cancer Chemother Pharmacol 2002;49:69-77.
30. Liu Y, Su W, Thompson EA, et al. Protein kinase CβII regulates its own expression in rat intestinal epithelial cells and the colonic epithelium in vivo. J Biol Chem 2004;279:45556-63.
31. Keyes K, Cox K, Treadway P, et al. An in vitro tumor model: analysis of angiogenic factor expression after chemotherapy. Cancer Res 2002;62:5597-602.
32. McNulty AM, Konicek BW, Lynch RL, et al. Enzastaurin (LY317615) suppresses signaling through the PKC and AKT pathways, inducing apoptosis, suppressing tumor-induced angiogenesis and reducing growth of human cancer xenografts. Proc AACR 2006;47:(abstr#1332).
33. Maier A, Fiebig HH, Thornton D, Lahn M. Antitumor activity of enzastaurin (LY317615) in human tumor xenografts in vitro. 18th EORTC-AACR-NCI Symposium on "Molecular Targets and Cancer Therapeutics"; Prague, Czech Republic. Eur J Cancer 2006;186.
34. Fiebig HH, Maier A, Burger AM. Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur J Cancer 2004;40:802-20.
35. Podar K, Raab MS, Zhang J, et al. Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Blood 2007;109:1669-77. Epub 2006 Oct 5.
36. Rizvi MA, Ghias K, Davies KM, et al. Enzastaurin (LY317615), a protein kinase Cβ inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines. Mol Cancer Ther 2006;5:1783-9.
37. Querfeld C, Rizvi MA, Kuzel TM, et al. The selective protein kinase Cβ inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. J Invest Dermatol 2006;126:1641-7.
38. Rieken M, Weigert O, Pastore A, et al. Inhibition of protein kinase Cβ by enzastaurin (LY 317615) induces alterations of key regulators of cell cycle and apoptosis in mantle cell lymphoma and synergizes with chemotherapeutic agents in a sequence dependent manner. ASH Annual Meeting Abstracts 2005;106:2416.
39. Rossi RM, Henn AD, Conkling R, et al. The PKCβ selective inhibitor, enzastaurin (LY317615), inhibits growth of human lymphoma cells. ASH Annual Meeting Abstracts 2005;106:1483.
40. Oberschmidt O, Eismann U, Schulz L , et al. Enzastaurin and pemetrexed exert synergistic antitumor activity in thyroid cancer cell lines in vitro. Int J Clin Pharmacol Ther 2005;43:603-4.
41. Oberschmidt O, Eismann U, Lahn MM, et al. In vitro chemosensitivity against enzastaurin correlates with gene expression of IL8 and GSK3-β. ASCO Annual Meeting Proceedings Part I [abstract 13046]. J Clin Oncol 2006.
42. Meinhold-Heerlein I, Bauerschlag DO, Bräutigam K, et al. Effects of PKCβ inhibitor enzastaurin on parental and chemoresistant ovarian cancer cell lines. ASCO Annual Meeting Proceedings Par t I [abstract 20037]. J Clin Oncol 2006;24.
43. Carducci MA, Musib L, Kies MS, et al. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase Cβ inhibitor, in patients with advanced cancer. J Clin Oncol 2006;24:4092-9.
44. Green LJ, Marder P, Ray C, et al. Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-β inhibitor. Clin Cancer Res 2006;12:3408-15.
45. Hanauske A, Weigang Koehler K, Yilmaz E, et al. Pharmacokinetic interaction and safety of enzastaurin and pemetrexed in patients with advanced or metastatic cancer. ASCO Annual Meeting Proceedings Part I [abstract 2047]. J Clin Oncol 2006.
46. Hanauske AR, Weigang-Kohler K, Yilmaz E , et al. Phase I study of pemetrexed followed by daily enzastaurin in patients with advanced or metastatic cancer. 18th EORCT-AACR-NCI Symposium on "Molecular Targets and Cancer Therapeutics", Prague, Czech Republic [abstract 64]. Eur J Cancer 2006;23.
47. Rademaker-Lakhai J, Beerepoot L, Witteveen E, et al. Phase I and pharmacokinetic evaluation of enzastaurin combined with gemcitabine and cisplatin in advanced cancer. Clin Cancer Res. In press.
48. Leong S, Camidge R, Eckhardt G, et al. A phase I dose-escalation and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced cancer. ASCO Annual Meeting Proceedings Part I [abstract 2048]. J Clin Oncol 2006.
49. Fine HA, Kim L, Royce C, et al. Results from phase II trial of enzastaurin (LY317615) in patients with recurrent high grade gliomas. ASCO Annual Meeting Proceedings [abstract 1504]. J Clin Oncol 2005.
50. Robertson M, Kahl B, Vose J, et al. A phase II study of enzastaurin, a protein kinase C-β inhibitor, in the treatment of relapsed diffuse large B-cell lymphoma. J Clin Oncol 2007;25:1741-6. Epub 2007 Mar 26.
51. Oh Y, Herbst R, Burris H, Cleverly A, Lahn M, Bepler G. A phase II study of enzastaurin as second or third-line treatment of non-small cell lung cancer (NSCLC). 18th EORCT-AACR-NCI Symposium on "Molecular Targets and Cancer Therapeutics"; Prague, Czech Republic [abstract 103]. Eur J Cancer 2006;35.
52. Watkins V, Hong S, Lin BK. Enzastaurin safety review: Data from phase I, phase II. trials. ASCO Annual Meeting Proceedings Part I [abstract 13077]. J Clin Oncol 2006.
53. Lahn M, McClelland P, Ballard D, Mintze K, Thornton D, Sandusky G. Immunohistochemical detection of protein kinase C-β (PKC-β) in tumour specimens of patients with non-small cell lung cancer. Histopathology 2006;49:429-31.
54. Barr LF, Campbell SE, Baylin SB. Protein kinase C-β 2 inhibits cycling and decreases c-myc-induced apoptosis in small cell lung cancer cells. Cell Growth Differ 1997;8:381-92.
55. Barr LF, Campbell SE, Penno MB, Ball DW, Baylin SB. Cell-substratum interactions mediate oncogene-induced phenotype of lung cancer cells. Cell Growth Differ1996;7:1149-56.
56. Paz -Ares L, Douillard P, Koralewski C, et al. Randomized phase III study of protein kinase C-α antisense oligonucleotide, aprinocarsen, with gemcitabine/cisplatin in patients with advanced stage non-small cell lung cancer. J Clin Oncol 2006;24:1428-34.
57. Monnerat C, Henriksson R, Chevalier T, et al. Phase I study of PKC412 (N-benzoyl-staurosporine), anovel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small cell lung cancer.
58. Lahn M, Su C, Li S, et al. Expression levels of protein kinase C-α in non-small-cell lung cancer. Clin Lung Cancer 2004;6:184-9.
59. Gupta AK, Soto DE, Feldman MD, et al. Signaling pathways in NSCLC as a predictor of outcome and response to therapy. Lung 2004;182:151-62.
60. Tang JM, He QY, Guo RY, et al. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 2006;51:181-91.
61. Herbst RS. Targeted therapy using novel agents in the treatment of non-small-cell lung cancer. Clin Lung Cancer 2002;3:S30-8.
62. Kerbel RS. Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results. J Clin Oncol 2001;19:45-51S.